What the Options Market Tells Us About Insulet

Deep-pocketed investors have adopted a bullish approach towards Insulet PODD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PODD usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Insulet. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 80% leaning bullish and 5% bearish. Among these notable options, 17 are puts, totaling $724,171, and 3 are calls, amounting to $144,000.

Projected Price Targets

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $165.0 to $180.0 for Insulet over the last 3 months.

Insights into Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Insulet's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Insulet's substantial trades, within a strike price spectrum from $165.0 to $180.0 over the preceding 30 days.

Insulet 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Present Market Standing of Insulet

• With a volume of 954,551, the price of PODD is up 0.66% at $167.0.
• RSI indicators hint that the underlying stock may be approaching oversold.
• Next earnings are expected to be released in 85 days.

Expert Opinions on Insulet

A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $221.4.

• An analyst from Jefferies persists with their Buy rating on Insulet, maintaining a target price of $260.
• Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Insulet, targeting a price of $200.
• An analyst from Wolfe Research has elevated its stance to Outperform, setting a new price target at $200.
• Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Insulet with a target price of $234.
• An analyst from Raymond James persists with their Outperform rating on Insulet, maintaining a target price of $213.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Insulet with Benzinga Pro for real-time alerts.